Literature DB >> 22870059

Neuraminidase Inhibitors from the Culture Broth of Phellinus linteus.

Ji-Hee Yeom1, In-Kyoung Lee, Dae-Won Ki, Myeong-Seok Lee, Soon-Ja Seok, Bong-Sik Yun.   

Abstract

During the search for neuraminidase inhibitors from medicinal fungi, we found that the culture broth of Phellinus linteus exhibited potent inhibitory activity. Solvent partition, Sephadex LH-20 column chromatography, and high-performance liquid chromatography (HPLC) were performed for purification of two active substances from the culture broth. According to (1)H NMR measurements and comparison of HPLC retention times with those of authentic compounds, their chemical structures were identified as hispidin and hypholomine B. Compounds (hispidin) 1 and 2 (hypholomine B) inhibited neuraminidase, with IC(50) values of 13.1 and 0.03 µM, respectively.

Entities:  

Keywords:  Hispidin; Hypholomine B; Neuraminidase inhibitor; Phellinus linteus

Year:  2012        PMID: 22870059      PMCID: PMC3408306          DOI: 10.5941/MYCO.2012.40.2.142

Source DB:  PubMed          Journal:  Mycobiology        ISSN: 1229-8093            Impact factor:   1.858


Mushrooms are nutritionally functional foods and important sources of physiologically beneficial medicines. They produce a large variety of secondary metabolites with unique chemical structures and interesting biological activities. Phellinus linteus is cultivated as a folk medicine in Korea and is known to exhibit various biological activities, such as anticancer, antioxidative, anti-angiogenic, anti-inflammatory and anti-viral effects [1-5]. However, except for polysaccharides, a limited number of bioactive metabolites have been reported from P. linteus. Neuraminidases, called sialidases, catalyze hydrolysis of terminal neuraminic-acid residues from newly formed virions and from host cell receptors [6], and are therefore involved in release of progeny virus from infected cells. Specifically, cleavage of the α-ketosidic bond linking a terminal neuraminic-acid residue to an adjacent oligosaccharide moiety by neuraminidase, which is also important for trafficking of virus in the mucus layer of the respiratory tract, allowing the virus access to underlying epithelial cells, has been reported [7]. Therefore, neuraminidase that plays an important role in viral proliferation is a drug target for the prevention of the spread of influenza infection. Neuraminidase inhibitors, such as zanamivir administered by inhalation and oseltamivir administered orally, have been used for combating influenza infection [8]. However, the long-term efficacy of these drugs is often limited by toxicity and the almost inevitable selection of drug-resistant viral mutants [9]. In our ongoing effort to identify bioactive substances from fungi, primarily medicinal fungi [10, 11], two neuraminidase inhibitors have been isolated from the culture broth of P. linteus (Fig. 1). This paper describes the isolation, structure determination, and neuraminidase inhibitory activity of these compounds.
Fig. 1

Structures of compounds 1 (hispidin) and 2 (hypholomine B).

A strain of P. linteus, which was obtained from the Rural Development Administration (RDA) in Korea, was grown in potato dextrose broth medium at 28℃ for 10 days. Extraction of three liters of the culture broth was performed using ethyl acetate, with vigorous shaking. Neuraminidase inhibitory activity was observed in the ethyl acetate-soluble portion. Following concentration of the ethyl acetate-soluble portion under reduced pressure, the concentrate was subjected to a Sephadex LH-20 (Pharmacia, Uppsala, Sweden) column eluted with methanol to give two active fractions. A Sephadex LH-20 column with 70% aqueous methanol was used for chromatography of one fraction, followed by purification with preparative reversed-phase high-performance liquid chromatography (HPLC) with 60% aqueous methanol with 0.04% trifluoroacetic acid to give compound 1. Sephadex LH-20 column chromatography, with 70% aqueous methanol, was performed for purification of the other fraction, followed by preparative reversed-phase HPLC using the same solvent used for compound 1 to afford compound 2. The chemical structure of compound 1 was determined according to 1H NMR spectrum and by comparison of HPLC retention time with that of the authentic compound. The 1H NMR spectrum of compound 1 in CD3OD exhibited signals due to a 1,2,4-trisubstituted benzene at δ 7.01 (d, J = 1.5 Hz), 6.93 (dd, J = 8.3, 1.5 Hz) and 6.76 (d, J = 8.3 Hz), two olefinic methines attributable to a trans-1,2-disubstituted double bond unit at δ 7.29 (d, J = 16.0 Hz) and 6.58 (d, J = 16.0 Hz), and a sp2 singlet methine at δ 6.09. These spectroscopic data were well matched with those of hispidin, which was previously isolated by our group as an antioxidant [12]. Thus, analytical HPLC equipped with a reversed-phase C18 column (150 × 4.6 mm i.d.) was performed for comparison of retention time of compound 1 with that of authentic hispidin. A linear gradient using water acidified with 0.04% trifluoroacetic acid (v/v) and methanol, at a flow rate of 1 mL/min, was used, starting at 10% aqueous methanol and reaching 100% methanol within a period of 30 min. Consequently, the retention time of compound 1 was the same as that of hispidin. Thus, compound 1 was identified as hispidin, a ubiquitous compound in genera Phellinus and Inonotus [12]. The structure of compound 2 was assigned using the same methods employed for compound 1. The 1H NMR spectrum of compound 2 in CD3OD exhibited signals due to two 1,2,4-trisubstituted benzenes at δ 7.03 (d, J = 2.0 Hz), 6.93 (dd, J = 8.3, 2.0 Hz), 6.72 (d, J = 8.3Hz) and 6.79 (d, J = 2.0 Hz), 6.78 (d, J = 8.3 Hz), 6.70 (dd, J = 8.3, 2.0 Hz), two olefinic methines attributable to a trans-1,2-disubstituted double bond unit at δ 7.35 (d, J = 16.1 Hz) and 6.63 (d, J = 16.1 Hz), two sp3 methines at δ 5.76 (d, J = 6.4 Hz) and 4.30 (d, J = 6.4 Hz), and two sp2 singlet methines at δ 6.36 and 6.08. Based on findings from an extensive literature survey, we observed that 1H NMR spectrum was in good agreement with that of hypholomine B [12]. Thus, analytical HPLC equipped with a reversed-phase C18 column (150 × 4.6 mm i.d.), using the same solvent used for compound 1, was performed for comparison of the retention time of compound 2 with that of authentic hypholomine B. Consequently, the retention time for compound 2 was the same as that of hypholomine B, revealing that compound 2 was identical to hypholomine B. A previously reported method, with minor modifications, was used in performance of the neuraminidase inhibition assay [13]. Briefly, 50 µL neuraminidase (N2876; Sigma, St. Louis, MO, USA) solution (0.05 U/mL) was pre-mixed with 10 µL of sample solution at different concentrations in 90 µL of 50 mM sodium acetate buffer (pH 5.0) in a cuvette. Then, 4-methylumbelliferyl-α-D-N-acetylneuraminic acid sodium salt hydrate (M8639; Sigma) 0.05 mM in buffer (pH 5.0) was added (50 µL) to the mixture as a substrate in order to start the reaction at 37℃. Quantification of 4-methylumbelliferone was performed immediately by fluorometric determination using a POLARstar OPTIMA multi-detection microplate reader (BMG Labtech, Offenburg, Germany). The excitation and emission wavelengths were 355 nm and 460 nm, respectively. As a result, compounds 1 and 2 exhibited neuraminidase inhibitory activity with IC50 values of 13.1 and 0.03 µM, respectively, in a dose-dependent manner (Fig. 2). Compound 2 induced potent inhibition of neuraminidase and exhibited approximately 430-times higher activity than compound 1. To the best of our knowledge, this is the first study to report on hispidin and hypholomine B as neuraminidase inhibitors. Details regarding the mode of action of hispidin and hypholomine B for inhibition of neuraminidase are under investigation.
Fig. 2

Neuraminidase inhibitory activity of compounds 1 (hispidin) and 2 (hypholomine B).

  13 in total

1.  Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.

Authors:  Ji Young Kim; Hyung Jae Jeong; Ji-Young Park; Young Min Kim; Su-Jin Park; Jung Keun Cho; Ki Hun Park; Young Bae Ryu; Woo Song Lee
Journal:  Bioorg Med Chem       Date:  2012-01-18       Impact factor: 3.641

2.  Neuraminidase pharmacophore model derived from diverse classes of inhibitors.

Authors:  Jian Zhang; KunQian Yu; Weiliang Zhu; Hualiang Jiang
Journal:  Bioorg Med Chem Lett       Date:  2006-03-10       Impact factor: 2.823

3.  Anti-angiogenic activity of methanol extract of Phellinus linteus and its fractions.

Authors:  Yeon Sil Lee; Yoon Hee Kim; Eun Kyung Shin; Dae Hwan Kim; Soon Sung Lim; Jae-Yong Lee; Jin-Kyung Kim
Journal:  J Ethnopharmacol       Date:  2010-06-08       Impact factor: 4.360

Review 4.  Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance.

Authors:  In-Kyoung Lee; Bong-Sik Yun
Journal:  J Antibiot (Tokyo)       Date:  2011-02-09       Impact factor: 2.649

5.  Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Authors:  Takeshi Ichinohe; Akira Ainai; Tomoyuki Nakamura; Yukihito Akiyama; Jun-Ichi Maeyama; Takato Odagiri; Masato Tashiro; Hidehiro Takahashi; Hirofumi Sawa; Shin-Ichi Tamura; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
Journal:  J Med Virol       Date:  2010-01       Impact factor: 2.327

Review 6.  A medicinal mushroom: Phellinus linteus.

Authors:  Tongbo Zhu; Sung-Hoon Kim; Chang-Yan Chen
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Antioxidant polyphenols from the mycelial culture of the medicinal fungi Inonotus xeranticus and Phellinus linteus.

Authors:  J-Y Jung; I-K Lee; S-J Seok; H-J Lee; Y-H Kim; B-S Yun
Journal:  J Appl Microbiol       Date:  2008-02-06       Impact factor: 3.772

8.  Phellinus linteus inhibits inflammatory mediators by suppressing redox-based NF-kappaB and MAPKs activation in lipopolysaccharide-induced RAW 264.7 macrophage.

Authors:  Ho Gyoung Kim; Deok Hyo Yoon; Won Ho Lee; Sang Kuk Han; Bhushan Shrestha; Chun Hoi Kim; Mi Hee Lim; Woochul Chang; Soyeon Lim; Sunga Choi; Won O Song; Jae Mo Sung; Ki Chul Hwang; Tae Woong Kim
Journal:  J Ethnopharmacol       Date:  2007-08-19       Impact factor: 4.360

Review 9.  The molecular biology of influenza virus pathogenicity.

Authors:  H D Klenk; R Rott
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

10.  Chemical Constituents of the Fruiting Body of Xylaria polymorpha.

Authors:  Yun-Woo Jang; In-Kyoung Lee; Young-Sook Kim; Soon-Ja Seok; Seung Hun Yu; Bong-Sik Yun
Journal:  Mycobiology       Date:  2009-09-30       Impact factor: 1.858

View more
  5 in total

1.  Styrylpyrones from Phellinus linteus Mycelia Alleviate Non-Alcoholic Fatty Liver by Modulating Lipid and Glucose Metabolic Homeostasis in High-Fat and High-Fructose Diet-Fed Mice.

Authors:  Chun-Hung Chiu; Chun-Chao Chang; Jia-Jing Lin; Chin-Chu Chen; Charng-Cherng Chyau; Robert Y Peng
Journal:  Antioxidants (Basel)       Date:  2022-04-30

Review 2.  Therapeutic Potential of Hispidin-Fungal and Plant Polyketide.

Authors:  Kseniia A Palkina; Daria A Ipatova; Ekaterina S Shakhova; Anastasia V Balakireva; Nadezhda M Markina
Journal:  J Fungi (Basel)       Date:  2021-04-22

3.  Chemical Constituents of the Culture Broth of Phellinus linteus and Their Antioxidant Activity.

Authors:  Myeong-Seok Lee; Byung Soon Hwang; In-Kyoung Lee; Geon-Sik Seo; Bong-Sik Yun
Journal:  Mycobiology       Date:  2015-03-31       Impact factor: 1.858

4.  Neuraminidase Inhibitors from the Fruiting Body of Phellinus igniarius.

Authors:  Ji-Yul Kim; Dae-Won Kim; Byung Soon Hwang; E-Eum Woo; Yoon-Ju Lee; Kyeong-Woon Jeong; In-Kyoung Lee; Bong-Sik Yun
Journal:  Mycobiology       Date:  2016-06-30       Impact factor: 1.858

5.  Neuraminidase Inhibitors from the Fermentation Broth of Phellinus linteus.

Authors:  Byung Soon Hwang; Myeong-Seok Lee; Seung Woong Lee; In-Kyoung Lee; Geon-Sik Seo; Hwa Jung Choi; Bong-Sik Yun
Journal:  Mycobiology       Date:  2014-06-30       Impact factor: 1.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.